Nearly 50% of Patients with Cardiac Device Infections Don’t Survive Beyond Three Years
The incremental mortality in implantable pacemaker and defibrillator
recipients who experience a device infection, compared to patients
without device infection, is substantial and persists for at least three
years after index hospitalization with infection. These are the key
findings of a retrospective cohort study of 200,219 Medicare
fee-for-service patients undergoing cardiac device procedures, with and
without infection, that were presented today by M. Rizwan Sohail, MD, a
researcher from the Mayo Clinic Divisions of Infectious Diseases and
Cardiovascular Diseases, at Heart Rhythm 2013, the Heart Rhythm
Societys 34 Annual Scientific Sessions.
Previously, Dr. Sohail and his collaborators have reported that patients
with cardiac device infections experience a two-fold increase in the
mortality rate one year after device implantation, compared to patients
without an infection. In this new study, Dr. Sohail and collaborators
looked at the long-term mortality three years after the device procedure
in 200,219 Medicare beneficiaries that underwent permanent pacemaker and
defibrillator procedures between January 1, 2007 and December 31, 2007,
including 5817 patients with cardiac device infections.
Key findings of the study included:
It is well known that cardiac device therapies such as pacemakers,
implanted cardioverter-defibrillators (ICDs), and cardiac
resynchronization therapy/defibrillators (CRT-Ds) can reduce morbidity
and mortality in appropriately selected patients, stated Dr. Sohail,
Unfortunately, these benefits can be significantly reduced, if the
implantation/replacement procedure is complicated by a device infection.
The focus of this study was to better understand the long-term mortality
associated with CIED infections, stratified for different cardiac device
This study was funded by TYRX, Inc.
Heart Rhythm 2013 is the most comprehensive educational program for
heart rhythm professionals, featuring more than 250 educational sessions
and more than 130 exhibitors showcasing innovative products and
services. The Heart Rhythm Societys Annual Scientific Sessions have
become the must-attend event of the year, allowing the exchange of new
vital ideas and information among colleagues from every corner of the
TYRX, Inc. commercializes innovative, implantable combination
drug+device products focused on infection control, including the AIGISRx
Antibacterial Envelope, designed to reduce surgical site infections
associated with Cardiac Implantable Electronic Devices (CIEDs). AIGISRx
products contain the antimicrobial agents, rifampin and minocycline,
which have been shown to reduce infection by pathogens responsible for
the majority of CIED infections, including superbugs such as
methicillin-resistant . (MRSA).*
*Data on file at TYRX and published Hansen . 2009; 32(7):898-907.
TYRX, Inc.Robert White, 732-246-8676President and Chief
Media:Kureczka/Martin AssociatesJoan Kureczka, 415-690-0210Joan@Kureczka-Martin.com
Source: TYRX, Inc.